Diagnostic role of plasma BNP levels in neonates with signs of congenital heart disease

International Journal of Cardiology

Volumn 147, Issue 1, 2011, Pages 42-46

  Davlouros, Periklis A ^a   Karatza, Ageliki A ^a   Xanthopoulou, Ioanna ^a   Dimitriou, Gabriel ^a   Georgiopoulou, Aikaterini ^a   Mantagos, Stefanos ^a   Alexopoulos, Dimitrios ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Congenital heart disease; Neonates; Plasma BNP

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ARTICLE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; CYANOTIC HEART DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ECHOCARDIOGRAPHY; HEART ATRIUM SEPTUM DEFECT; HEART LEFT RIGHT SHUNT; HEART MURMUR; HEART VENTRICLE SEPTUM DEFECT; HEMODYNAMICS; HORMONE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN INTENSIVE CARE; PATENT DUCTUS ARTERIOSUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY DISTRESS; SENSITIVITY AND SPECIFICITY; TERTIARY HEALTH CARE; UNIVERSITY HOSPITAL;

AGE FACTORS; BIOLOGICAL MARKERS; HEART DEFECTS, CONGENITAL; HUMANS; INFANT, NEWBORN; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS;

EID: 79951721321     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.07.029     Document Type: Article

References (25)

1. Loffredo CA. Epidemiology of cardiovascular malformations: prevalence and risk factors. Am J Med Genet 2000;97:319-25. (Pubitemid 32463497)
2. Silberbach M, Hannon D. Presentation of congenital heart disease in the neonate and young infant. Pediatr Rev/Am Acad Pediatr 2007;28:123-31. (Pubitemid 46683319)
3. Pina IL, O'Connor C. BNP-guided therapy for heart failure. JAMA 2009;301:432-4.
4. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30. (Pubitemid 30172933)
5. Lainscak M, von Haehling S, Anker SD. Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers. Int J Cardiol 2009;132:303-11.
6. El-Khuffash A, Molloy EJ. Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates? Arch Dis Child 2007;92:F320-4.
7. Mir TS, Falkenberg J, Friedrich B, et al. Levels of brain natriuretic peptide in children with right ventricular overload due to congenital cardiac disease. Cardiol Young 2005;15:396-401. (Pubitemid 41388036)
8. Kunii Y, Kamada M, Ohtsuki S, et al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama 2003;57:191-7. (Pubitemid 37386876)
9. Koch A, Zink S, Singer H. B-type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J 2006;27:861-6.
10. Czernik C, Lemmer J, Metze B, et al. B-type natriuretic peptide to predict ductus intervention in infants <28 weeks. Pediatr Res 2008;64:286-90.
11. Cowley CG, Bradley JD, Shaddy RE. B-type natriuretic peptide levels in congenital heart disease. Pediatr Cardiol 2004;25:336-40. (Pubitemid 38989516)
12. Farombi-Oghuvbu I,Matthews T,Mayne PD, et al. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus. Arch Dis Child 2008;93:F257-60.
13. Sanjeev S, Pettersen M, Lua J, et al. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol 2005;25:709-13.
14. Flynn PA, da Graca RL, Auld PA, et al. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. J Pediatr 2005;147:38-42. (Pubitemid 40981143)
15. Choi BM, Lee KH, Eun BL, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005;115:e255-61.
16. Chiruvolu A, Punjwani P, Ramaciotti C. Clinical and echocardiographic diagnosis of patent ductus arteriosus in premature neonates. Early Hum Dev 2009;85:147-9.
17. YasueH, Yoshimura M, Sumida H, et al. Localization andmechanismof secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203. (Pubitemid 24203680)
18. Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart (British Cardiac Society) 2003;89:875-8. (Pubitemid 36920810)
19. Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 2003;45:249-54. (Pubitemid 36995093)
20. Law YM, Keller BB, Feingold BM, et al. Usefulness of plasma B-type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Am J Cardiol 2005;95:474-8. (Pubitemid 40247541)
21. Cannesson M, Bionda C, Gostoli B, et al. Time course and prognostic value of plasma B-type natriuretic peptide concentration in neonates undergoing the arterial switch operation. Anesth Analg 2007;104:1059-65 tables of contents.
22. Bolger AP, Sharma R, Li W, et al. Neurohormonal activation and the chronic heart failure syndrome in adultswith congenital heart disease. Circulation 2002;106:92-9. (Pubitemid 34747447)
23. Davlouros PA, Kilner PJ, Hornung TS, et al. Right ventricular function in adults with repaired tetralogy of Fallot assessed with cardiovascular magnetic resonance imaging: detrimental role of right ventricular outflow aneurysms or akinesia and adverse right-to-left ventricular interaction. J Am Coll Cardiol 2002;40:2044-52. (Pubitemid 35425375)
24. Davlouros PA, Niwa K, Webb G, et al. The right ventricle in congenital heart disease. Heart (British Cardiac Society) 2006;92(Suppl 1):i27-38.
25. Coats AJ. Ethical authorship and publishing. Int J Cardiol 2009;131:149-50.